Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04700332
PHASE2

PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

Sponsor: Hoag Memorial Hospital Presbyterian

View on ClinicalTrials.gov

Summary

The standard of care imaging of prostate cancer metastases recommended by the National Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be suboptimal. PyL is a novel PET tracer designed to detect prostate specific membrane antigen (PSMA) expressed on prostate cancer cells. PyL PET/CT may provide improved evaluation of clinically significant metastases in patients with prostate cancer.

Official title: 2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (PyL) in Patients With High Risk and Biochemically Recurrent Prostate Cancer

Key Details

Gender

MALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

184

Start Date

2021-02-01

Completion Date

2022-12-15

Last Updated

2021-07-27

Healthy Volunteers

No

Conditions

Interventions

DRUG

DCFPyL PET/CT

Prostate Membrane Specific Antigen-specific imaging

Locations (1)

Hoag Memorial Hospital Presbyterian

Irvine, California, United States